CN111566216B - 使用可调节内含子的表达控制 - Google Patents

使用可调节内含子的表达控制 Download PDF

Info

Publication number
CN111566216B
CN111566216B CN201880068443.0A CN201880068443A CN111566216B CN 111566216 B CN111566216 B CN 111566216B CN 201880068443 A CN201880068443 A CN 201880068443A CN 111566216 B CN111566216 B CN 111566216B
Authority
CN
China
Prior art keywords
sequence
nucleic acid
cng
cells
intron
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880068443.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN111566216A (zh
Inventor
格拉哈姆·怀特西德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AskBio UK Ltd
Original Assignee
Synpromics Ltd
AskBio UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synpromics Ltd, AskBio UK Ltd filed Critical Synpromics Ltd
Priority to CN202410738295.6A priority Critical patent/CN118562839A/zh
Publication of CN111566216A publication Critical patent/CN111566216A/zh
Application granted granted Critical
Publication of CN111566216B publication Critical patent/CN111566216B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201880068443.0A 2017-08-23 2018-08-22 使用可调节内含子的表达控制 Active CN111566216B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410738295.6A CN118562839A (zh) 2017-08-23 2018-08-22 使用可调节内含子的表达控制

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1713545.0 2017-08-23
GBGB1713545.0A GB201713545D0 (en) 2017-08-23 2017-08-23 Expression control using a regulatable intron
PCT/GB2018/052387 WO2019038544A1 (en) 2017-08-23 2018-08-22 EXPRESSION CONTROL USING AN ADJUSTABLE INTRON

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410738295.6A Division CN118562839A (zh) 2017-08-23 2018-08-22 使用可调节内含子的表达控制

Publications (2)

Publication Number Publication Date
CN111566216A CN111566216A (zh) 2020-08-21
CN111566216B true CN111566216B (zh) 2024-07-02

Family

ID=59996625

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880068443.0A Active CN111566216B (zh) 2017-08-23 2018-08-22 使用可调节内含子的表达控制
CN202410738295.6A Pending CN118562839A (zh) 2017-08-23 2018-08-22 使用可调节内含子的表达控制

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410738295.6A Pending CN118562839A (zh) 2017-08-23 2018-08-22 使用可调节内含子的表达控制

Country Status (8)

Country Link
US (2) US11492618B2 (enExample)
EP (1) EP3673068A1 (enExample)
JP (2) JP7830029B2 (enExample)
CN (2) CN111566216B (enExample)
AU (2) AU2018319637B2 (enExample)
GB (1) GB201713545D0 (enExample)
IL (2) IL314845A (enExample)
WO (1) WO2019038544A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3171636A1 (en) * 2020-03-26 2021-09-30 Graham WHYTESIDE Forskolin-inducible promoters and hypoxia-inducible promoters
US20230407327A1 (en) * 2020-03-26 2023-12-21 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production
WO2021209743A1 (en) * 2020-04-15 2021-10-21 Synpromics Limited Forskolin-inducible promoters and hypoxia-inducible promoters
JP7898267B2 (ja) * 2021-10-20 2026-07-31 リファインホールディングス株式会社 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
WO2025024776A2 (en) * 2023-07-27 2025-01-30 Duke University Compositions comprising xbp1 fragments and methods of use in gene therapy
WO2026015884A1 (en) * 2024-07-11 2026-01-15 Helix Nanotechnologies Inc Compositions comprising ire-1 binding sequences and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004081143A (ja) * 2002-08-28 2004-03-18 Inst Of Physical & Chemical Res 生体刺激存在下でのｍＲＮＡのフレームシフトを利用した蛋白質の発現方法
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
AU2003268356A1 (en) * 2002-08-30 2004-03-19 President And Fellows Of Harvard College Methods and compositions for modulating xbp-1 activity
US20070111258A1 (en) * 2005-06-22 2007-05-17 Kaufman Randal J Compositions and methods for modulating the acute phase response
US8227184B2 (en) * 2008-01-14 2012-07-24 President And Fellows Of Harvard College Methods for modulating de novo hepatic lipogenesis by modulating XBP-1 activity
WO2010151827A1 (en) * 2009-06-25 2010-12-29 Bayer Healthcare Llc X-box binding proteins (xbp-1) variants and methods of using the same
US20200393447A1 (en) * 2017-07-09 2020-12-17 Thomas Hughes Biosensors for measuring cell signaling in stressed and healthy cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004081143A (ja) * 2002-08-28 2004-03-18 Inst Of Physical & Chemical Res 生体刺激存在下でのｍＲＮＡのフレームシフトを利用した蛋白質の発現方法
WO2021195491A2 (en) * 2020-03-26 2021-09-30 Asklepios Biopharmaceutical, Inc. Inducible promoter for viral vector production

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
A conformational RNA zipper promotes intron ejection during non-conventional XBP1 mRNA splicing;Peschek J等;EMBO Rep;第16卷(第16期);摘要，第1689页左栏第2段，图1，图EV1 A *

Also Published As

Publication number Publication date
EP3673068A1 (en) 2020-07-01
JP2023118937A (ja) 2023-08-25
US11492618B2 (en) 2022-11-08
AU2018319637A1 (en) 2020-03-12
JP2020533019A (ja) 2020-11-19
US20200199593A1 (en) 2020-06-25
JP7830029B2 (ja) 2026-03-16
IL314845A (en) 2024-10-01
CA3073366A1 (en) 2019-02-28
IL272800B1 (en) 2024-09-01
NZ761945A (en) 2024-09-27
GB201713545D0 (en) 2017-10-04
IL272800B2 (en) 2025-01-01
WO2019038544A1 (en) 2019-02-28
AU2025205352A1 (en) 2025-07-31
IL272800A (en) 2020-04-30
US12600969B2 (en) 2026-04-14
AU2018319637B2 (en) 2025-04-10
CN118562839A (zh) 2024-08-30
CN111566216A (zh) 2020-08-21
US20230304003A1 (en) 2023-09-28

Similar Documents

Publication Publication Date Title
US12600969B2 (en) Expression control using a regulatable intron
KR102851101B1 (ko) Rna를 편집하기 위한 방법 및 조성물
CN115651927B (zh) 编辑rna的方法和组合物
CA3018904C (en) Novel minimal utr sequences
AU2009212833B2 (en) Sirna-mediated gene silencing with viral vectors
US20040053876A1 (en) siRNAs and uses therof
EP2166107A1 (en) Lentiviral vectors for the expression of shRNA
JP2005517450A (ja) 短干渉核酸（ｓｉＮＡ）を用いるＲＮＡ干渉媒介性標的発見および標的評価
JP2013520158A (ja) タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作
JP2005535356A (ja) 遺伝子サイレンシングに関する方法および組成物
Qiu et al. Clean-PIE: a novel strategy for efficiently constructing precise circRNA with thoroughly minimized immunogenicity to direct potent and durable protein expression
Bhakta et al. Double MS2 guided restoration of genetic code in amber (TAG), opal (TGA) and ochre (TAA) stop codon
JP2026509506A (ja) リボザイム媒介ｒｎａアセンブリおよび発現
JP2023517581A (ja) ＣＰＲ富化メタゲノム由来のＣＲＩＳＰＲ－Ｃａｓヌクレアーゼ
AU2004256322A1 (en) siRNA expression system
HK40114268A (en) Expression control using a regulatable intron
CA3073366C (en) Expression control using a regulatable intron
US12365900B2 (en) miRNA switches for RNA-triggered control of RNA interference
JP2015180203A (ja) タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作
WO2006130976A1 (en) Interfering rnas, methods for their production, and use
RU2839162C2 (ru) Молекула олигомерной нуклеиновой кислоты и ее применение
HK40081918B (en) Methods and compositions for editing rna
HK40061041A (en) Methods and compositions for editing rnas
JPWO2006006520A1 (ja) 新規創薬標的の探索方法
HK40056042B (en) Methods and compositions for editing rnas

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Country or region after: United Kingdom

Address after: Edinburgh

Applicant after: Asbio UK Ltd.

Address before: Edinburgh

Applicant before: Synpromics Ltd.

Country or region before: United Kingdom

CB02 Change of applicant information
GR01 Patent grant